The MHRA’s Interim Executive Director of Science and Research writes in The British Medical Journal on the approval of the UK’s first new UTI antibiotic in nearly 30 years, and the wider challenge of tackling antibiotic resistance.
Similar Posts
MHRA Safety Roundup: August 2025
Summary of the latest safety advice for medicines and medical device users
Field Safety Notices: 11 to 15 August 2025
List of Field Safety Notices from 11 to 15 August 2025.
MHRA approves adrenaline nasal spray – the first needle-free emergency treatment for anaphylaxis in the UK
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 18 July 2025, approved adrenaline (epinephrine) nasal spray (EURneffy) to be used for the emergency treatment of serious allergic reactions, known as anaphylaxis.
Field Safety Notices: 23-27 February 2026
List of Field Safety Notices from 23-27 February 2026.
Decision: Marketing authorisations Granted in 2026
Marketing authorisations Granted in 2026.
Guidance: A guide to defective medicinal products
Reporting, investigating and recalling suspected defective medicinal products to the Defective Medicines Report Centre (DMRC).